Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies

Patients with anti-TIF1γ autoantibodies have a substantially elevated risk of an underlying or imminent malignancy — a clinical association strong enough that anti-TIF1γ positivity routinely prompts intensive cancer screening. Yet not every anti-TIF1γ-positive patient develops cancer, and there is no validated way to predict which ones will. The investigators used Phage ImmunoPrecipitation Sequencing (PhIP-Seq) on serum from 43 dermatomyositis patients in whom standard line-blot testing had not detected any of the known DM-specific autoantibodies. The screen surfaced reactivity against Sp4, a transcription factor not previously implicated in DM autoimmunity.

The team confirmed Sp4 as a true autoantigen by immunoprecipitating full-length Sp4 protein with patient sera, then built an ELISA and screened large clinical cohorts. What emerged was a striking pattern. Anti-Sp4 autoantibodies appeared almost exclusively in DM patients who were also anti-TIF1γ-positive. And among those dual-positive patients, cancer was conspicuously absent. In the Johns Hopkins discovery cohort, none of the 26 anti-TIF1γ/anti-Sp4 dual-positive patients had cancer, compared with 14% of TIF1γ-positive patients lacking anti-Sp4. An independent University of Pittsburgh validation cohort reproduced the effect: 13.3% cancer in the dual-positive arm versus 67.7% in the TIF1γ-only arm.

For rheumatologists and oncologists co-managing TIF1γ-positive DM patients, anti-Sp4 testing offers a route to right-size cancer surveillance — though the biological mechanism is not yet established and prospective studies are needed before clinical adoption. The Sp4/TIF1γ result also illustrates how the joint distribution of autoantibody specificities can re-stratify risk inside an otherwise homogeneous serological group — the kind of unbiased, proteome-scale autoantibody discovery that programmable phage-display platforms were built to enable.